Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Osivelotor (GBT021601) in Renal Impairment
NCT05878704Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osivelotor in sickle cell disease (SCD), sponsored by Pfizer. Primary endpoints: Concentration of GBT021601 in whole blood and plasma up to 112 Days and Single-dose PK parameters up to 112 Days. Started Jun 2023; status: terminated.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT05878704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878704.